Mitochondria‐targeted atovaquone (Mito‐ATO) in situ vaccination eliminates tumor cells by activating systemic CD4+ T response through blocking both granulocytic‐myeloid‐derived suppressor cells (G‐MDSCs) and regulatory T cells (Tregs). Here, CD4 is linked to neoplasm.